Transfusion Medicine and Hemostasis

1. Blood banking and transfusion medicine – the field, the discipline and the industry <br>2. Quality principles in Transfusion medicine <br>3. Regulatory issues in transfusion medicine <br>4. Role of the physician in the blood center <br>5. Blood donor, donation process and technical aspects of blood collection <br>6. Apheresis blood component collections <br>7. Recipient-specific blood donations <br>8. Adverse donor reactions (iron) <br>9. Component preparation and manufacturing <br>10. Serologic testing of donor products <br>11. Overview of infectious disease testing <br>12. HIV screening <br>13. Hepatitis B screening <br>14. Hepatitis C screening <br>15. WNV screening <br>16. Zika screening <br>17. Babesia screening <br>18. Syphilis, HTLV and Chagas screening <br>19. Bacterial mitigation of platelets <br>20. Role of the transfusion service physician <br>21. Pretransfusion testing <br>22. Antibody identification <br>23. Direct antiglobulin test <br>24. Molecular DNA based blood group typing <br>25. ABO and H blood group systems <br>26. RH and RhAg blood group system <br>27. KELL and KIDD blood group systems <br>28. MNS AND DUFFY blood group systems <br>29. LEWIS, I P1Pk and Glob blood group systems <br>30. Other blood group systems, collections, and antigens <br>31. Human platelet and neutrophil antigens <br>32. HLA Antigens <br>33. Red blood cells products <br>34. Plasma products <br>35. Platelet products (to include PAS if not previously mentioned; was mentioned In the 2nd edition) <br>36. Cryoprecipitate and fibrinogen concentrates <br>37. Granulocyte products <br>38. Albumin and related products <br>39. Human immunoglobuin preparations <br>40. Rh immune globulin <br>41. Coagulation Factor products <br>42. Platelet rich plasma <br>43. Convalescent plasma, including COVID convalescent plasma <br>42. Nonfactor therapies for bleeding disorders <br>44. Blood Pharming and alternative blood production methods <br>45. Irradiation of blood products <br>44. Leukoreduction of blood products <br>46. CMV-safe blood products <br>47. Frozen blood products <br>48. Washed blood products <br>49. Volume reduced blood products <br>50. Pathogen reduction technologies <br>51. Intrauterine, Neonatal and pediatric transfusion medicine <br>52. Perinatal transfusion medicine <br>53. AutoImmune hemolytic anemias <br>54. Transfusion management in patients with hemoglobinopathies <br>55. Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplantation <br>56. Transfusion of Patients Undergoing Solid Organ Transplantation <br>57. Transfusion support and hemostatic monitoring in patients connected to extracorporeal devices <br>58. Transfusion of patients receiving antithrombotic therapy <br>59. Blood transfusion in economically restricted and developing countries <br>60. Management of Patients Who Refuse Blood Transfusion <br>61. Platelet transfusion refractory patients <br>62. Massive transfusion <br>63. Patient blood management <br>64. Overview of adverse events and outcomes following transfusion <br>65. Febrile non-hemolytic transfusion reactions <br>66. Allergic transfusion reactions <br>67. Acute hemolytic transfusion reactions <br>68. Delayed hemolytic transfusion reactions <br>69. Transfusion-Associated Circulatory Overload <br>70. Transfusion-Related Acute Lung Injury <br>71. Septic transfusion reactions <br>72. Metabolic, hypotensive and other acute reactions and complications <br>73. Post transfusion purpura <br>74. Transfusion associated graft versus host disease <br>75. Transfusion related immunomodulation <br>76. Iron Overload <br>77. Transfusion transmitted diseases <br>78. Overview to therapeutic apheresis<br>79. Therapeutic plasma exchange <br>80. Therapeutic erythrocytapheresis <br>81. Therapeutic thrombocytapheresis <br>82. Therapeutic leukocytapheresis and adsorptive cytapheresis <br>83. Extracorporeal photopheresis <br>84. LDL apheresis <br>85. Immunoabsorption <br>86. COVID-19 & Apheresis <br>87. Therapeutic phlebotomy <br>88. Overview of cellular therapy <br>89. HPC products derived from bone marrow and peripheral blood <br>90. Cord blood banking (expansion) <br>91. Regenerative medicine (iPS) <br>92. Immunotherpy (T cells): CAR-T, TILs, gene therapy and more <br>93. Adverse events associated with HPC product infusion <br>94. Quality and regulatory issues in cellular therapy <br>95. Tissue banking in the hospital setting <br>96. Overview of the coagulation system <br>97. Approach to the patient with a bleeding disorder <br>98. Congenital thrombocytopenia <br>99. fetal and Neonatal alloimmune thrombocytopenia <br>100. Acquired neonatal thrombocytopenia <br>101. Bernard Soulier syndrome and other GPIb-IX-V related receptor defects <br>102. Glanzmann's thrombocytopenia <br>103. Other platelet glycoprotein disorders <br>104. Platelet storage-granule defects <br>105. Failure to release and aspirin-like defects <br>106. Other Platelet abnormalities <br>107. Acquired platelet disorders <br>108. Acute (childhood) ITP <br>109. Chronic ITP <br>110. Drug induced thrombocytopenia <br>111. Heparin induced thrombocytopenia <br>112. Vaccine Induced Thrombotic Immune Thrombocytopenia <br>113. Autoimmune lymphoproliferative syndrome <br>114. Hemolytic uremic syndrome <br>115. Thrombotic thrombocytopenic purpura <br>116. Antiphospholipid syndrome <br>117. Von Willebrand Disease <br>118. Hemophilia A <br>119. Hemophilia B <br>120. Congenital disorders of fibrinogen <br>121. Factor XIII, D α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 deficiencies <br>122. Factor XI deficiency <br>123. Factor VII deficiency <br>124. Factor II, factor V, and factor X deficiencies <br>125. Bleeding disorders in pregnancy <br>126. Vascular bleeding disorders <br>127. Hemostasis in Liver Disease <br>128. Bleeding risks with Vitamin K deficiency <br>129. Bleeding risks with cardiac disease <br>130. Bleeding risks with renal disease <br>131. Bleeding risks with cancer <br>132. Disseminated intravascular coagulopathy <br>133. coagulopathy in sickle cell disease and other hemoglobiniopathies <br>134. COVID coagulopathy <br>135. Thrombosis in COVID Coagulopathy---Anticoagulation guidelines <br>136. Bleeding in COVID coagulopathy <br>137. Acquired coagulation factor inhibitors <br>138. Overview of purposes of hemostasis testing and common sources of error <br>139. Pediatric reference ranges in coagulation testing  <br>140. Prothrombin Time <br>141. Activated Partial Thrombolplastin Time <br>142. Mixing studies <br>143. Coagulation Factor Testing <br>144. Testing of Nonfactor therapies: emicizumab <br>145: Testing of Nonfactor therapies: inhibitors of anticoagulant pathways (fitusiran and concizumab) <br>146. Specific Factor Inhibitor Testing <br>147. Thrombin time and Fibrinogen Evaluation <br>148. laboratory diagnosis of inherited von Willebrand Disease <br>149. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome <br>150. Laboratory Assessment of Treatment of von Willebrand’s Disease <br>151. Measurement of platelet count, mean platelet volume, and reticulated platelets <br>152. Platelet Function Analyzer <br>153. thromboelastography/thromboelastometry <br>154. Platelet Aggregation Studies <br>155. Laboratory Diagnosis of Platelet Functional Defects <br>156. Confirmatory testing for diagnosis of platelet disorders <br>157. Platelets in COVID coagulopathy <br>158. Anti-platelet Therapy Monitoring <br>159. Laboratory evaluation of factor XIII deficiency <br>160. Fibrinolytic testing<br>161. Age-adjusted D-Dimer cut offs to rule out PE/ VTE 162. Laboratory techniques in fibrinolysis testing <br>163. Laboratory evaluation of long-term thrombophilic disorders <br>164. Thrombophilia testing in children <br>165. Antithrombin Testing <br>166. Protein C deficiency evaluation <br>167. Protein S deficiency evaluation <br>168. testing for Activated Protein C Resistance <br>169. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in inherited thrombophilia <br>170. Chronic elevated levels of Factor VIII and other coagulation factors <br>171. Laboratory Monitoring for Heparins, fondaparinux, direct thrombin inhibitors, and oral anti-Xa medications <br>172: DOAC interferences in coagulation testing <br>173. Laboratory testing in patients receiving DOAC antidotes <br>174. Laboratory support for warfarin monitoring <br>175. Molecular testing in Coagulation <br>176. Acquired prothrombotic conditions <br>177: Ventricular assist device: anticoagulation monitoring <br>178. Laboratory Evaluation of Heparin-Induced Thrombocytopenia <br>179. Laboratory Evaluation of Thrombotic Thromcytopenic Purpura <br>180. D-Dimer testing in COVID coagulopathy <br>181. Other coagulation tests in COVID coagulopathy <br>182. Laboratory diagnosis of lupus anticoagulant and anti-phopholipid antibodies <br>183. Lupus anticoagulant testing in COVID-19 <br>184. Circulating microparticles <br>185. Thrombin Generation Assays <br>186. Laboratory testing of contact factors <br>187. Contact factors and complements <br>188. Monitoring of new anticoagulants---inhibitors of contact factors <br>189. Reference ranges in transgender